

FORM 2B**LISTING SUMMARY**

Issuer Name:	Cresco Labs Inc.
Listing Statement Date:	November 30, 2018
Descriptions of securities to be listed:	Subordinate Voting Shares. Each Subordinate Voting Share gives the holder thereof one (1) vote per share. The Proportionate Voting Shares and the Super Voting Shares are not listed.
Address:	Cresco Labs Inc.'s head office is located at 520 W Erie St #220, Chicago, IL 60654 and registered office is located at Suite 2200, 1055 West Hastings Street, Vancouver, BC V6E 2E9
Brief Description of the Issuer's Business:	Cresco Labs Inc. will engage in the business of cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation and the distribution of such products to medical or adult use consumers in legalized cannabis markets.
Company Contact:	John Schetz
Phone:	(312) 410-8226
Fax:	N/A
E-mail:	John.schetz@crescolabs.com
Description of securities outstanding:	Subordinate Voting Shares, Proportionate Voting Shares, Super Voting Shares, options and warrants.
Symbol:	CL
Type:	Subordinate Voting Shares
Number:	21,873,969
CUSIP:	Subordinate Voting Shares (Canadian) [CUSIP 22587M106] Subordinate Voting Shares (REG D) [CUSIP 22587M403]
If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event:	N/A
Dates of Press Release and Any Public Filings Concerning the Event:	Press Release Announcing Proposed Reverse Takeover with Cresco Labs, LLC filed on SEDAR on October 10, 2018 Management Information Circular of predecessor, Randsburg filed on SEDAR on October 19, 2018

Jurisdiction of Incorporation:	British Columbia																		
Website:	www.crescolabs.com																		
Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled):	Last Shareholders' Meeting – November 14, 2018																		
Fiscal Year End:	December 31 st																		
Financial Information as at:	Condensed Interim Financial Statements filed by Randsburg International Gold Corp. as at November 23, 2018																		
Board of Directors:	<table border="1"> <tr> <td>Charles Bachtell</td> <td>CEO and Director</td> </tr> <tr> <td>Joe Caltabiano</td> <td>President and Director</td> </tr> <tr> <td>Dominic A. Sergi</td> <td>Director</td> </tr> <tr> <td>Brian McCormack</td> <td>Director</td> </tr> <tr> <td>Robert M. Sampson</td> <td>Director</td> </tr> <tr> <td>John R. Walter</td> <td>Director</td> </tr> <tr> <td>Gerald Corcoran</td> <td>Director</td> </tr> <tr> <td>Thomas Manning</td> <td>Director</td> </tr> <tr> <td>Randy Podolsky</td> <td>Director</td> </tr> </table>	Charles Bachtell	CEO and Director	Joe Caltabiano	President and Director	Dominic A. Sergi	Director	Brian McCormack	Director	Robert M. Sampson	Director	John R. Walter	Director	Gerald Corcoran	Director	Thomas Manning	Director	Randy Podolsky	Director
Charles Bachtell	CEO and Director																		
Joe Caltabiano	President and Director																		
Dominic A. Sergi	Director																		
Brian McCormack	Director																		
Robert M. Sampson	Director																		
John R. Walter	Director																		
Gerald Corcoran	Director																		
Thomas Manning	Director																		
Randy Podolsky	Director																		

	Current (\$) ⁽¹⁾	Previous (\$)
Current Assets:	\$188,464,397	\$45,619,602
Working Capital:	\$175,615,771	\$40,259,729
Total assets:	\$374,113,783	\$74,465,442
Long-term liabilities:	\$1,894,076	\$1,894,076
Shareholders' equity (deficiency):	\$179,680,815	\$13,853,773

⁽¹⁾ Pro-forma financial information as at November 30, 2018 after giving effect to the acquisition as if it had been completed on that date.